ArticleArchives of orthopaedic and trauma surgery2026
Tranexamic acid reduces transfusion requirements after pelvic osteotomy: a nationwide propensity score-matched analysis.
Article in Archives of orthopaedic and trauma surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPelvic osteotomy is frequently associated with substantial perioperative blood loss due to the highly vascularized pelvic anatomy. Tranexamic acid (TXA) is widely used to reduce blood loss in total hip arthroplasty; however, evidence supporting its use in pelvic osteotomy, particularly in Asian populations, remains limited. This study evaluated the association between perioperative TXA use, transfusion requirements, and postoperative complications in patients undergoing pelvic osteotomy in Japan. MATERIALS AND
methodsUsing the Japanese Diagnosis Procedure Combination nationwide administrative database, we retrospectively identified patients who underwent pelvic osteotomy between December 2011 and March 2023. Patients receiving perioperative TXA were compared with those who did not, using one-to-one propensity score matching. Outcomes included transfusion rates on postoperative days 0–2, cumulative transfusion volume, and in-hospital complications, including infection, deep vein thrombosis, pulmonary embolism (PE), and reoperation.
resultsAfter matching, 3,542 patients were included in each group. TXA use was independently associated with a significantly lower likelihood of blood transfusion on postoperative days 0 (95% CI, 0.552–0.693; p < 0.05) and 1 (95% CI, 0.472–0.579; p < 0.05). The cumulative transfusion volume over the first three postoperative days was significantly lower in the TXA group than in the non-TXA group (598.8 ± 408.0 g vs. 728.6 ± 426.5 g; p < 0.05). While autologous transfusion use differed, allogeneic transfusion rates were comparable. Subgroup analysis demonstrated that this reduction in overall transfusion was primarily attributable to a significantly lower utilization of autologous blood transfusion, whereas allogeneic transfusion rates were comparable between the groups. No significant increase in infection, PE, or reoperation was observed.
conclusionsPerioperative TXA use was associated with reduced transfusion requirements after pelvic osteotomy without compromising short-term safety, supporting its use within contemporary perioperative management in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.